Compare the glucose homeostasis and some biomarkers of diabetes among control, parvastatin and rosuvastatin groups.

Glucose and insulin response during OGTT. Some markers of insulin resistance and insulin secretion calculated from OGTT.

Incidence of diabetes [ Time Frame: 5 to 10 years. ] [ Designated as safety issue: No ]

We will repeat FPG and A1C every 6 months and OGTT every 1-2 years for up to 10 years to investigate the incidence of diabetes.

Chronic complications of diabetes [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]

Diabetic retinopathy: Development of advanced diabetic retinopathy. Advanced diabetic retinopathy was defined as development of proliferative diabetic retinopathy, retinopathy treated with laser photocoagulation or vitrectomy.

Incidence of diabetes [ Time Frame: 5 to 10 years. ] [ Designated as safety issue: No ]

We will repeat FPG and A1C every 6 months and OGTT every 1-2 years for up to 10 years to investigate the incidence of diabetes.

Chronic complications of diabetes [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]

Diabetic retinopathy: Development of advanced diabetic retinopathy. Advanced diabetic retinopathy was defined as development of proliferative diabetic retinopathy, retinopathy treated with laser photocoagulation or vitrectomy.

The Statins on Glucose Homeostasis in Subjects With Impaired Fasting Glucose

Official Title ICMJE

The Influence of Statins on Glucose Homeostasis and the Biomarkers of Diabetes in Subjects With Impaired Fasting Glucose

Brief Summary

Evaluate the effects of rosuvastatin (maybe the highest diabetogenic) and pravastatin (seems to be protective) on the glucose homeostasis and other biomarkers in subjects with impaired fasting glucose.

Detailed Description

Statin therapy effectively reduces cardiovascular events. However, trial data1 and meta-analyses suggest that statins also confer increased risk of development of diabetes. In order to elucidate whether statins increase risk of diabetes, investigators conducted this study to evaluate the effects of rosuvastatin (maybe the highest diabetogenic) and pravastatin (seems to be protective) on the glucose homeostasis and other biomarkers in subjects with impaired fasting glucose.